Location History:
- Lansdale, PA (US) (2003)
- New Hope, PA (US) (2009 - 2023)
Company Filing History:
Years Active: 2003-2023
Title: The Innovative Contributions of Chi Luo
Introduction
Chi Luo is an accomplished inventor based in New Hope, PA (US). He holds a total of 6 patents that reflect his dedication to advancing medical technology. His work primarily focuses on drug delivery systems and pharmaceutical compositions aimed at treating significant health issues.
Latest Patents
One of Chi Luo's latest patents is a transdermal drug delivery system designed to alleviate acute and chronic musculoskeletal pain. This innovative system comprises a backing layer, an adhesive layer, a topical applicator, a suitable quantity of drug, and a topical carrier. The topical applicator is engineered to enhance the delivery of medication through the skin, thereby improving patient comfort and treatment efficacy.
Another notable patent involves novel 2-amino-quinazoline derivatives that serve as inhibitors of β-secretase (BACE). This invention is particularly relevant for the treatment of Alzheimer's disease and related disorders. The compounds developed by Luo are designed to inhibit β-secretase, which plays a crucial role in the progression of Alzheimer's disease.
Career Highlights
Chi Luo has made significant strides in the pharmaceutical industry, having worked with reputable companies such as Janssen Pharmaceutica. His contributions to drug development and delivery systems have positioned him as a key figure in the field of medical innovation.
Collaborations
Throughout his career, Chi Luo has collaborated with notable professionals, including Allen B Reitz and Yifang Huang. These partnerships have further enriched his research and development efforts.
Conclusion
Chi Luo's innovative work in drug delivery systems and pharmaceutical compositions demonstrates his commitment to improving healthcare solutions. His patents not only highlight his expertise but also contribute to advancements in medical technology that can significantly impact patient care.